11. 364OClinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC. (24th November 2019) Authors: Mezquita, L; Planchard, D; Suarez, M Dorta; Aldea, M; Naltet, C; Lamberts, V; Grecea, M; Martin-Romano, P; de Kievit, F; Jovelet, C; Lacroix, L; Masip, J Remon; Lavaud, P; Gazzah, A; Morris, C; Howarth, K; Green, E; Vassal, G; Massard, C; Besse, B Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. 3OApplicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials. (27th February 2019) Authors: Varga, A; Bernard-Tessier, A; Auclin, E; Mezquita Pérez, L; Baldini, C; Planchard, D; Marabelle, A; Hollebecque, A; Besse, B; Massard, C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. 420PPhase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours. (23rd October 2018) Authors: Bono, P; Massard, C; Peltola, K; Azaro, A; Italiano, A; Kristeleit, R S; Lassen, U N; Arkenau, H-T; Hakulinen, P; Garratt, C; Ikonen, T; Mustonen, M; Rodon, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. 424P_PRInclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: A reality or a myth?. (23rd October 2018) Authors: Vozy, A; Berlanga Charriel, P; Geoerger, B; Massard, C; Gaspar, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. 439PProspective validation of prognostic scores to improve patient selection for immuno-oncology trials. (23rd October 2018) Authors: Massard, C; Segal, N H; Cho, D C; Papadimitrakopoulou, V A; Rizvi, N A; Cho, B C; Yu, L; Yang, H; Hsieh, H-J; Zhang, J; Zhao, W; Gao, G; Guo, X; Abdullah, S; Englert, J; Soria, J-C; Dar, M; Roskos, L; Ferte, C; Antonia, S J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. 443TiPFirst-in-human trial design for W0101: A first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population. (23rd October 2018) Authors: Gomez-Roca, C A; Garralda-Cabanas, E; Cruzalegui, F; Ausseil, F; Zorza, G; Delfour, O; Besse, J; Akla, B; Gautier, S; Adam, J; Lacroix-Triki, M; Passioukov, A; Roche, R; Pavlyuk, M; Massard, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. 49P Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study. (15th December 2019) Authors: Bravo, P; Vss, B; Baldini, C; Romano, P Martin; Hollebecque, A; Varga, A; Vuagnat, P; Champiat, S; Marabelle, A; Escudier, B; Albiges, L; Loriot, Y; Massard, C; Cataldi, A; Babai, S; Voisin, A-L; Lambotte, O; Annereau, M; Michot, J-M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. 54P Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors. (15th December 2019) Authors: Vuagnat, P; Auclin, E; Mezquita, L; Alfonso, J Adeva; Tocino, M R Vidal; Munoz, F Longo; El Dakdouki, Y; Romano, P Martin; Baldini, C; Varga, A; Garcia-Carbonero, R; Besse, B; Massard, C; Hollebecque, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. 59OPreliminary results on mechanisms of resistance to ALK inhibitors: A prospective cohort from the MATCH-R study. (16th September 2018) Authors: Recondo, G; Mezquita, L; Bigot, L; Galissant, J; Frias, R L; André, F; Massard, C; Soria, J-C; Besse, B; Friboulet, L Journal: Annals of oncology Issue: Volume 29:Number 6(2018)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. (22nd May 2019) Authors: Henon, C; Blay, J -Y; Massard, C; Mir, O; Bahleda, R; Dumont, S; Postel-Vinay, S; Adam, J; Soria, J -C; Le Cesne, A Journal: Annals of oncology Issue: Volume 30:Number 8(2019) Page Start: 1401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗